FDA 483 - Acrotech Biopharma Inc. - January 19, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
ACROTECH BIOPHARMA, Inc. in East Windsor, NJ, was inspected regarding its post-marketing surveillance activities. The inspection revealed significant deficiencies in adverse drug experience reporting, including failures to submit serious and unexpected adverse drug experiences within 15 days, adequately investigate reported cases, and provide supporting scientific literature for alert reports. These issues indicate a systemic problem with the firm's pharmacovigilance processes.
ID · c4443168-9cc6-4195-b415-a2f6e0a9ce09